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Bisphenol A is an industrial chemical widely used in plastic
products with a consequent exposure to humans. To assess
whether exposure to bisphenol A is associated with renal
disease, we searched for low-grade albuminuria in 3055
Chinese adults in the Shanghai metropolitan area aged
40 years or older. Using a value for urinary albumin-to-
creatinine ratioso30mg/g, we examined its association with
urinary bisphenol A. Participants in the highest compared to
the lowest quartile of urinary bisphenol A concentrations
were significantly more likely to have low-grade albuminuria.
Multivariate stepwise linear regression analysis, adjusted
for potential confounding factors, showed that urinary
bisphenol A was an independent determinant of the urinary
albumin-to-creatinine ratio significantly associated with an
increased risk of low-grade albuminuria with an adjusted
odds ratio of 1.23 for the highest compared to the lowest
concentration quartiles. This association was not modified by
conventional risk factors such as age, gender, smoking,
alcohol consumption, body mass index, hypertension,
diabetes, and the estimated glomerular filtration rate. There
was no significant relationship between bisphenol A and
combined micro- and macroalbuminuria. Thus, our study
lends support to a potential relation between bisphenol A
exposure and an increased risk of low-grade albuminuria.
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Microalbuminuria, conventionally defined as a urinary
albumin excretion (spot urine albumin-to-creatinine ratio)
of 30 to o300mg/g,1 is recognized as a risk factor for
cardiovascular morbidity and mortality.2–5 There is growing
evidence from prospective studies that urinary albumin-
to-creatinine ratio levels less than the current microalbumin-
uria threshold (low-grade albuminuria) are associated with
an increased risk of incident cardiovascular diseases.6,7
Bisphenol A, which is widely used to produce polycarbo-
nate plastic and epoxy resins and usually found in water
bottles and food containers, is one of the environmental
endocrine disruptors.8,9 Bisphenol A has estrogen-mimicking
effect and may interact with estrogen receptors.10–12
Humans are extensively exposed to bisphenol A. The US
Centers for Disease Control and Prevention found bisphenol
A was in the urine of 95% of US adults.13,14 Animal studies
have suggested that exposure to bisphenol A might lead to
abnormal metabolism of glucose and lipids, and exacerbate
the development of cardiovascular diseases.15–19 However,
epidemiological data about the relationship between bis-
phenol A exposure and human health were surprisingly
lacking. Recently, in the National Health and Nutrition
Examination Survey (NHANES) 2003–2004 and 2005–2006,
it was found that higher urinary bisphenol A concentrations
were associated with various diseases including cardio-
vascular diseases and type 2 diabetes.20,21 However, no
studies have examined the associations between low-grade
albuminuria, an early marker of cardiovascular diseases, and
bisphenol A exposure.
In this study, we aim to assess the association between
bisphenol A exposure and low-grade albuminuria in a large
sample of Chinese adults.
RESULTS
Basic characteristics
The general characteristics of all the 3455 study participants
are presented in Table 1. Overall, the mean age was 60.8 years
(s.d.: 9.9). Of these 3455 participants, 2034 (58.9%) were
women. The median urinary bisphenol A was 0.81 ng/ml
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(interquartile range: 0.48–1.44 ng/ml). Approximately 11% of
the participants reported having cardiovascular diseases
(including coronary heart disease, angina, and myocardial
infarction) and 142 (4.1%) reported taking angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker
drugs. In addition, there were 640 participants with estimated
glomerular filtration rate p90ml/min per 1.73m2. Accord-
ing to the 75-g oral glucose tolerance test (OGTT) diagnosis
criteria, 1087 (31.5%) had diabetes, 748 (21.6%) had
impaired glucose regulation, and 1588 (46.0%) had normal
glucose regulation.
There were 333 participants with microalbuminuria and
67 with macroalbuminuria. Among participants without
micro- and macroalbuminuria, the quartile ranges of urinary
albumin-to-creatinine ratio were 0–2.50, 2.51–5.03, 5.04–9.70,
and 9.71–29.9mg/g. Compared with those who had normal
urinary albumin excretion, those with low-grade albuminuria
(defined as urinary albumin-to-creatinine ratio between 9.71
and 29.9mg/g) had significantly higher urinary bisphenol A
levels (0.95 with interquartile range 0.54–1.72 vs. 0.79 with
interquartile range 0.46–1.37 ng/ml; Po0.0001). However,
there was no significant difference in urinary bisphenol A
between the group with normal urinary albumin excretion
and that with micro- and macroalbuminuria.
Association between bisphenol A and low-grade albuminuria
To evaluate the association between bisphenol A and low-
grade albuminuria, a total of 3055 participants without
micro- and macroalbuminuria were included in the analysis.
The clinical and biochemical characteristics according to
the quartiles of bisphenol A are presented in Table 2.
Compared with the participants in the lowest quartile
(o0.48 ng/ml), those in the highest quartile of urinary
bisphenol A concentration (X1.45 ng/ml) were more likely to
be men, were younger, had higher proportions of current
smokers and drinkers, and higher body mass index, waist
circumference, estimated glomerular filtration rate, fasting
plasma glucose, but had lower systolic blood pressure, total
cholesterol, and high-density lipoprotein cholesterol (all
Po0.05). The median of urinary albumin-to-creatinine
ratio in the highest quartile of urinary bisphenol A (6.41,
interquartile range: 3.11–11.47mg/g) was significantly higher
than that in the lowest quartile (4.42, interquartile range:
2.30–8.50mg/g) (Po0.0001). Participants in the highest
quartiles of urinary bisphenol A were more likely to have
low-grade albuminuria than those in the lowest quartile
(30.9% vs. 21.1%, Po0.0001) (Table 2).
As shown in Table 3, Pearson’s correlation analyses
revealed that age, sex, current smoking, the use of angio-
tensin-converting enzyme inhibitor or angiotensin receptor
blocker drugs, body mass index, waist circumference, systolic
blood pressure, diastolic blood pressure, estimated glomerular
filtration rate, triglycerides, total cholesterol, high-density
lipoprotein cholesterol, fasting plasma glucose, post-loading
plasma glucose, hemoglobin A1c, index of homeostasis
model assessment of insulin resistance (HOMA-IR), high-
sensitivity C-reactive protein, and urinary bisphenol A were
significantly correlated with urinary albumin-to-creatinine
Table 1 | Characteristics of participants
Mean±s.d./median (interquartile range)/number (%)
Overall
(N=3455)
Normal urinary albumin
excretion (N=2291)
Low-grade
albuminuria (N=764)
Micro- and macroalbuminuria
(N=400)
Bisphenol A (ng/ml) 0.81 (0.48–1.44) 0.79 (0.46–1.37) 0.95 (0.54–1.72) 0.77 (0.46–1.39)
Age (years) 60.8±9.9 60.3±9.8 60.8±10.1 63.7±10.5
Female 2034 (58.9) 1330 (58.1) 495 (64.8) 209 (52.3)
Current smokers 699 (20.2) 498 (21.7) 144 (18.8) 57 (14.3)
Current drinkers 531 (15.4) 373 (16.3) 123 (16.1) 35 (8.8)
Use of ACEI or ARB drugs 142 (4.1) 87 (3.8) 33 (4.3) 22 (5.5)
Body mass index (kg/m2) 25.3±3.7 25.0±3.6 25.7±3.7 26.5±4.2
Waist circumference (cm) 87.1±9.9 86.4±9.8 87.8±10.1 90.5±10.0
Systolic blood pressure (mmHg) 138.6±21.9 135.3±20.5 142.8±22.4 151.4±23.5
Diastolic blood pressure (mmHg) 78.4±10.2 77.3±9.7 80.3±10.8 81.7±10.8
Estimated glomerular filtration rate
(ml/min per 1.73m2)
112.2±25.4 111.9±23.3 114.5±27.9 108.8±32.0
Triglycerides (mmol/l) 1.44 (1.00–2.08) 1.38 (0.96–1.99) 1.48 (1.04–2.17) 1.67 (1.16–3.84)
Total cholesterol (mmol/l) 5.15±0.99 5.12±0.98 5.18±0.98 5.26±1.07
High-density lipoprotein cholesterol (mmol/l) 1.36±0.31 1.37±0.31 1.34±0.31 1.31±0.29
Low-density lipoprotein cholesterol (mmol/l) 2.39±0.69 2.37±0.67 2.42±0.71 2.42±0.74
Fasting plasma glucose (mmol/l) 5.2 (4.8–6.0) 5.1 (4.7–5.8) 5.3 (4.8–6.4) 5.7 (5.0–7.8)
Post-loading plasma glucose (mmol/l) 7.9 (6.2–12.3) 7.5 (6.0–10.8) 8.7 (6.7–13.9) 12.0 (7.4–19.0)
Hemoglobin A1c (%) 6.1 (5.8–6.7) 6.1 (5.7–6.5) 6.2 (5.8–7.1) 6.6 (6.0–8.3)
HOMA-IR 1.7 (1.1–2.8) 1.6 (1.0–2.5) 2.0 (1.2–3.1) 2.5 (1.6–4.3)
High-sensitivity C-reactive protein (mg/l) 0.20 (0.06–0.85) 0.17 (0.06–0.66) 0.26 (0.08–0.97) 0.47 (0.11–2.25)
Urinary albumin-to-creatinine ratio (mg/g) 5.81 (2.74–12.42) 3.65 (2.00–5.94) 14.5 (11.7–19.2) 59.1 (39.9–98.0)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HOMA-IR, homeostasis model assessment of insulin resistance.
Data are means±s.d. or medians (interquartile ranges) or numbers (proportions).
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ratio (Po0.05). The multivariable stepwise linear regression
analysis demonstrated that sex, systolic blood pressure,
diastolic blood pressure, fasting plasma glucose, hemoglobin
A1c, high-sensitivity C-reactive protein, and bisphenol A
were independent determinants of urinary albumin-to-
creatinine ratio.
Table 2 | General characteristics by quartiles of urinary bisphenol A concentrations among participants without micro- and
macroalbuminuria
Mean±s.d./median (interquartile range)/number (%)
Quartile 1
(N=768)
Quartile 2
(N=762)
Quartile 3
(N=759)
Quartile 4
(N=766) P#
Bisphenol A (ng/ml) 0.30 (0.15–0.39) 0.63 (0.56–0.72) 1.05 (0.92–1.21) 2.28 (1.75–3.27) o0.0001
Age (years) 62.8±10.2 61.1±9.7* 59.3±9.5*,w 58.5±9.36*,w o0.0001
Female 531 (69.1) 454 (59.6)* 438 (57.7)* 402 (52.4)*,w,y o0.0001
Current smokers 103 (13.4) 165 (21.7)* 165 (21.7)* 209 (27.3)*,w,y o0.0001
Current drinkers 86 (11.2) 131 (17.2)* 120 (15.8)* 159 (20.7)*,y o0.0001
Use of ACEI or ARB drugs 29 (3.8) 29 (3.9) 32 (4.2) 30 (3.9) 0.84
Body mass index (kg/m2) 24.9±3.5 25.2±3.6 25.3±3.8 25.4±3.5* 0.043
Waist circumference (cm) 85.9±9.6 87.2±9.6* 86.9±9.8 87.7±9.8* 0.0038
Systolic blood pressure (mmHg) 140.1±22.7 137.7±21.8* 136.3±20.6* 134.7±19.3*,w o0.0001
Diastolic blood pressure (mmHg) 77.7±10.7 77.6±10.1 78.6±9.8 78.2±9.8 0.24
Estimated glomerular filtration rate (ml/min per 1.73m2) 110.4±25.1 111.8±23.7 113.6±25.2* 114.5±24.0*,w 0.0053
Triglycerides (mmol/l) 1.43 (1.00–2.05) 1.40 (0.97–1.99) 1.42 (0.99–2.07) 1.40 (0.98–2.00) 0.77
Total cholesterol (mmol/l) 5.16±1.02 5.18±0.98 5.13±0.98 5.08±0.92* 0.17
High-density lipoprotein cholesterol (mmol/l) 1.39±0.33 1.37±0.32 1.35±0.29* 1.33±0.29*,w 0.0006
Low-density lipoprotein cholesterol (mmol/l) 2.39±0.77 2.38±0.69 2.38±0.69 2.40±0.64 0.90
Fasting plasma glucose (mmol/l) 5.2 (4.7–5.8) 5.2 (4.8–6.0)* 5.1 (4.8–5.8) 5.1 (4.8–6.0) 0.04
Post-loading plasma glucose (mmol/l) 7.8 (6.1–11.3) 7.7 (6.1–11.8) 7.5 (6.1–11.0) 7.8 (6.2–12.2) 0.27
Hemoglobin A1c (%) 6.1 (5.8–6.6) 6.2 (5.8–6.7)* 6.1 (5.8–6.6) 6.1 (5.8–6.7) 0.11
HOMA-IR 1.6 (1.0–2.5) 1.7 (1.0–2.8) 1.7 (1.1–2.6) 1.7 (1.1–2.8) 0.65
High-sensitivity C-reactive protein (mg/l) 0.19 (0.06–0.82) 0.19 (0.06–0.84) 0.17 (0.05–0.63) 0.21 (0.07–0.76)y 0.13
Urinary albumin-to-creatinine ratio (mg/g) 4.42 (2.30–8.50) 4.51 (2.41–8.95) 5.24 (2.47–10.19) 6.41 (3.11–11.47)*,w,y o0.0001
Low-grade albuminuria 162 (21.1) 167 (21.9) 198 (26.1)* 237 (30.9)*,w,y o0.0001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ANOVA, analysis of variance; ARB, angiotensin receptor blocker; HOMA-IR, homeostasis model assessment of
insulin resistance.
*Compared with quartile 1, Po0.05.
wCompared with quartile 2, Po0.05.
yCompared with quartile 3, Po0.05.
#P-values are based on ANOVA test.
Data are means±s.d. or medians (interquartile ranges) or numbers (proportions).
Table 3 | Simple correlation and multiple stepwise linear regression analysis on log (urinary albumin-to-creatinine ratio)
among participants without micro- and macroalbuminuria
Univariate Stepwise
r P Standardized b±s.e.m. P
Age (years) 0.08 o0.0001 — —
Sex (male=1, female=0) 0.08 o0.0001 0.12±0.02 o0.0001
Current smokers (yes=1, no=0) 0.05 0.007 — —
Current drinkers (yes=1, no=0) 0.01 0.53 — —
Use of ACEI or ARB drugs (yes=1, no=0) 0.04 0.03 — —
Body mass index (kg/m2) 0.12 o0.0001 — —
Waist circumference (cm) 0.11 o0.0001 — —
Systolic blood pressure (mmHg) 0.23 o0.0001 0.16±0.0005 o0.0001
Diastolic blood pressure (mmHg) 0.14 o0.0001 0.05±0.001 0.007
Estimated glomerular filtration rate (ml/min per 1.73m2) 0.07 0.0001 — —
Log10 triglycerides (mmol/l) 0.10 o0.0001 — —
Total cholesterol (mmol/l) 0.05 0.002 — —
High-density lipoprotein cholesterol (mmol/l) 0.04 0.01 — —
Low-density lipoprotein cholesterol (mmol/l) 0.03 0.05 — —
Log10 fasting plasma glucose (mmol/l) 0.21 o0.0001 0.10±0.008 0.0004
Log10 post-loading plasma glucose (mmol/l) 0.22 o0.0001 — —
Log10 hemoglobin A1c (%) 0.22 o0.0001 0.09±0.09 0.002
Log10 HOMA-IR 0.20 o0.0001 — —
Log10 high-sensitivity C-reactive protein (mg/l) 0.16 o0.0001 0.09±0.005 o0.0001
Log10 bisphenol A (mg/g) 0.09 o0.0001 0.07±0.02 o0.0001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HOMA-IR, homeostasis model assessment of insulin resistance.
r, Pearson correlation coefficient; b, regression coefficient.
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In the univariable logistic regression model, participants
in the highest quartile of urinary bisphenol A were more
likely to have low-grade albuminuria compared with those
in the lowest quartile (odds ratio (OR): 1.68, 95% confidence
intervals (95% CI) 1.33–2.12; Po0.0001), and those in the
third quartile (0.82pbisphenol Ao1.45 ng/ml) were also
more likely to have low-grade albuminuria (OR: 1.31, 95% CI
1.03–1.66; P¼ 0.028). The test for the trend was significant
(P for trendo0.0001). After adjusting for age, sex, and body
mass index, participants in the highest and third quartiles
were still more likely to have low-grade albuminuria
compared with those in the lowest quartile, respectively
(adjusted OR: 1.80, 95% CI 1.41–2.29, Po0.0001; and 1.39,
95% CI 1.09–1.78, P¼ 0.0079). Further adjustments for other
potential confounding factors including age, sex, smoking
and drinking status, the use of angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker drugs,
body mass index, systolic blood pressure, diastolic blood
pressure, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, estimated glomerular filtration rate,
fasting plasma glucose, post-loading plasma glucose, hemo-
globin A1c, HOMA-IR, and high-sensitivity C-reactive
protein did not materially change the magnitudes of the
associations (adjusted ORs for the highest vs. the lowest
quartile: 1.23, 95% CI 1.13–1.34, Po0.0001, and for the third
vs. the lowest quartile: 1.20, 95% CI 1.06–1.37, P¼ 0.005).
The tests for the trend in the multivariable analyses were all
significant (P for trend o0.0001) (Table 4).
Finally, we conducted stratified analyses to determine the
ORs of low-grade albuminuria with each 1 s.d. increase
in log-bisphenol A in subgroups of the strata variables.
According to stratified analyses, the associations between
urinary bisphenol A concentration and the risk of low-grade
albuminuria were significant in both age strata (o60 and
X60 years), both sex strata (male and female), both body
mass index strata (o25 and X25 kg/m2), both smoking
status (yes and no), both drinking status (yes and no), both
hypertension strata (yes and no), both diabetes strata
according to the OGTT diagnosis criteria (yes and no), and
both estimated glomerular filtration rate strata (o90 and
X90ml/min per 1.73m2). Nevertheless, interactions between
urinary bisphenol A and these risk factors were not
significant (P40.05) (Figure 1).
The associations between urinary bisphenol A concen-
tration and the risk of low-grade albuminuria were not
significant in those with high-sensitivity C-reactive protein
X3.0mg/l (N¼ 297 among these 3055). Test for the inter-
action between urinary bisphenol A and high-sensitivity
C-reactive protein was also not significant.
Association between bisphenol A and greater-grade
albuminuria
The 400 participants with micro- or macroalbuminuria were
included in the analysis. No significant relationships between
bisphenol A and combined micro- and macroalbuminuria
were observed (adjusted ORs for the highest vs. the lowest
quartile: 1.24, 95% CI 0.87–1.77; for the third vs. the lowest
quartile: 1.07, 95% CI 0.75–1.53; and for the second vs. the
lowest quartile: 1.10, 95% CI 0.87–1.77) (Table 5).
DISCUSSION
In this study of Chinese adults with the urinary albumin-
to-creatinine ratio less than the current microalbuminuria
threshold, we found that higher urinary bisphenol A
concentrations were significantly associated with an increased
risk of low-grade albuminuria, independent of conventional
risk factors.
Although animal studies have shown that bisphenol A was
an endocrine disruptor and had an estrogen-mimicking
effect,11,22,23 epidemiological studies on the relationship
between bisphenol A exposure and human diseases are
sparse. Recently, Lang et al.20 performed a cross-sectional
analysis in 1,500 individuals from the NHANES 2003–2004.
They found that higher urinary bisphenol A concentrations
were associated with various diseases including cardio-
vascular diseases. A later updated analysis by the same
Table 4 | Associations of urinary bisphenol A concentration with low-grade albuminuria
Bisphenol A category
Model 1 Model 2 Model 3
ORs (95% CI) P ORs (95% CI) P ORs (95% CI) P
Low-grade albuminuria (n=764)a
Quartile 1 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Quartile 2 1.05 (0.82–1.34) 0.72 1.08 (0.84–1.38) 0.56 1.11 (0.85–1.44) 0.44
Quartile 3 1.31 (1.03–1.66) 0.028 1.39 (1.09–1.78) 0.0079 1.20 (1.06–1.37) 0.005
Quartile 4 1.68 (1.33–2.12) o0.0001 1.80 (1.41–2.29) o0.0001 1.23 (1.13–1.34) o0.0001
P for trend o0.0001 o0.0001 o0.0001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin
resistance; OR, odds ratios.
aLow-grade albuminuria was defined as urinary albumin-to-creatinine ratio between 9.71 to 29.9mg/g according to the highest quartile of urinary albumin-to-creatinine ratio
in participants without micro- and macroalbuminuria (n=764).
Model 1: unadjusted.
Model 2: adjusted for age, sex, and body mass index.
Model 3: adjusted for all the potential confounding factors including age, sex, smoking and drinking status, use of ACEI or ARB drugs, body mass index, systolic blood
pressure, diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, estimated glomerular filtration rate, fasting plasma glucose, post-
loading plasma glucose, hemoglobin A1c, HOMA-IR, and high-sensitivity C-reactive protein.
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research group in NHANES 2005–2006 confirmed the asso-
ciations.21 However, the supporting data from other popula-
tions are still lacking.
Previous studies have confirmed that there is an increased
risk of cardiovascular diseases and death associated with
microalbuminuria.24–28 Recent studies demonstrated that
urinary albumin excretion less than the current micro-
albuminuria threshold also significantly predicted cardio-
vascular diseases.5,7,29,30–34 The data from the Framingham
Heart Study indicated that low levels of urinary albumin
excretion less than the current microalbuminuria threshold
(30mg/g) predicted a more rapid progression toward
Total
OR 95% CI
1.80 (1.44–2.24) < 0.0001
<0.0001
< 0.0001
0.022
0.0006
< 0.0001
0.017
< 0.0001
0.033
< 0.0001
0.0004
< 0.0001
0.0084
< 0.0001
0.0010
0.0052
0.80
< 0.0001
< 0.0001
1.52 (1.06–2.17)
2.08 (1.57–2.75)
1.91 (1.40 –2.59)
1.73 (1.27–2.37)
1.80 (1.41–2.29)
1.89 (1.12–3.19)
1.82 (1.44–2.31)
1.85 (1.05–3.26)
1.95 (1.41–2.69)
1.71 (1.27–2.30)
2.10 (1.52–2.89)
1.49 (1.11–2.00)
1.83 (1.39–2.41)
1.83 (1.28–2.63)
2.15 (1.26–3.68)
1.78 (1.40 –2.27)
1.90 (1.51–2.40)
1.09 (0.55–2.16)
P-value
Sex
Male
Female
Age
< 60 years
60 years
Smoking status
No
Yes
No
Yes
< 25 kg/m2
25 kg/m2
Hypertension
No
Yes
No
Yes
0.0 0.5 1.0 1.5
Odds ratios for low -grade albuminuria
2.0 2.5 3.0 3.5 4.0
< 90 ml/min per 1.73 m2
90 ml/min per 1.73 m2
< 3.0 mg/l
3.0 mg/l
High-sensitivity C-reactive protein
Estimated glomerular filtration rate
Diabetes
Body mass index
Drinking status
Figure 1 |Adjusted odds ratios (OR) for each 1 s.d. increase in log bisphenol A concentration associated with the risk of low-grade
albuminuria. All models are adjusted for potential confounding factors including age, sex, smoking and drinking status, the use of
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker drugs, body mass index, systolic blood pressure, diastolic blood
pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, estimated glomerular filtration rate, fasting plasma
glucose, post-loading plasma glucose, hemoglobin A1c, homeostasis model assessment of insulin resistance, and high-sensitivity C-reactive
protein. CI, confidence interval.
Table 5 | Associations of urinary bisphenol A concentration with combined micro- and macroalbuminuria
Bisphenol A category
Model 1 Model 2 Model 3
ORs (95% CI) P ORs (95% CI) P ORs (95% CI) P
Micro- and macroalbuminuria (n=400)a
Quartile 1 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Quartile 2 1.07 (0.78–1.47) 0.68 1.12 (0.81–1.55) 0.82 1.10 (0.78–1.56) 0.98
Quartile 3 0.97 (0.70–1.35) 0.62 1.05 (0.75–1.48) 0.72 1.07 (0.75–1.53) 0.81
Quartile 4 1.06 (0.76–1.47) 0.75 1.21 (0.87–1.70) 0.33 1.24 (0.87–1.77) 0.29
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin
resistance; OR, odds ratios.
aWe defined participants with normal urinary albumin excretion as 0 (n=2291) and those with combined micro- (n=333) and macroalbuminuria (n=67) as 1.
Model 1: unadjusted.
Model 2: adjusted for age, sex, and body mass index.
Model 3: adjusted for all the potential confounding factors including age, sex, smoking and drinking status, use of ACEI or ARB drugs, body mass index, systolic blood
pressure, diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, estimated glomerular filtration rate, fasting plasma glucose,
post-loading plasma glucose, hemoglobin A1c, HOMA-IR, and high-sensitivity C-reactive protein.
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vascular diseases in healthy subjects, and, in the long term, an
increased incidence of cardiovascular disease events.29,35 In
another study, Arnlo¨v et al.29 reported that the cutoff for an
elevated cardiovascular event rate was 3.9mg/g of urinary
albumin-to-creatinine ratio for men and 7.5mg/g of urinary
albumin-to-creatinine ratio for women. Data from the
HOPE study showed that the risk of cardiovascular events
increased with the urinary albumin-to-creatinine ratio and
suggested that any degree of albuminuria is a risk factor for
cardiovascular diseases.34 The MONICA/KORA Augsburg
Echocardiographic Substudy also reported that low-grade
albuminuria with urinary albumin-to-creatinine ratio of
4.0–10.0mg/g was associated with an increased cardio-
vascular risk.32 Therefore, low-grade albuminuria is well
established as one of the risk factors for cardiovascular
diseases, suggesting that urinary bisphenol A might be related
to cardiovascular risks.
There is still no well-agreed explanation of the mechan-
isms for the effect of bisphenol A on early urine albumin
excretion, but it is now widely accepted that bisphenol A not
only has the efficacy of estradiol but is also equally potent
with regard to several of its effects.36–38 Bisphenol A was
considered a weak environmental estrogen because of its
relatively low affinity for the estrogen receptors compared
with estradiol.36,37,39,40 Bisphenol A has a rapid, non-genomic
promoting effect by binding to not a classical estrogen
receptors, but rather G-protein–coupled non-classical mem-
brane estrogen receptors, bisphenol A also can promote cell
proliferation by activating protein kinase A/cyclic AMP-
responsive element binding protein and protein kinase G
rapid signaling pathways in various cell types, including
endothelial cells.38 Studies in both diabetic patients and
general individuals indicated that elevated urinary albumin
excretion was associated with abnormalities in endothelial
function.41–44 On the basis of the results of these studies,
the non-genomic promoting effect on endothelial function by
bisphenol A may have a potential role in affecting urinary
albumin excretion.
In addition, by decreasing antioxidant enzymes and
increasing hydrogen peroxide and lipid peroxidation, bis-
phenol A induces oxidative stress, which takes an important
part in the pathogenesis of endothelial injury and abnormal
albuminuria.1,5,14 In addition, bisphenol A has been known
to increase insulin mimics of estradiol and influence the
insulin-secreting beta cells and glucagon-secreting alpha cells
of the pancreas, and then leads to hyperinsulinemia and
finally to insulin resistance, a factor contributing to the
development of elevated urinary albumin excretion.45,46
In addition, as low-grade albuminuria is a predictor for
chronic kidney diseases or diabetic nephropathy, it is possible
that bisphenol A exposure might also contribute to renal
disease progression.30 However, no significant relation-
ships between bisphenol A and combined micro- and
macroalbuminuria were found in our study. As micro- and
macroalbuminuria were greater-grade manifestation of renal
injury, it is likely that there are more metabolic risk factors
associated with micro- and macroalbuminuria, some of which
might veil the effect of bisphenol A. However, the underlying
reason remains unexplained and requires further exploration.
Our study is the first to examine the association between
bisphenol A exposure and low-grade albuminuria in Chinese
adults. The strengths of our investigation include the large
community-based cohort of individuals. In addition, we have
measured a wide spectrum of lifestyle and biochemical risk
factors, which allow a careful control for the potential
confounding effects in the analyses.
There are several limitations to be considered. First,
because of the cross-sectional nature of this study, we cannot
conclude a causal relationship between bisphenol A and low-
grade albuminuria. We will pursue to examine the prospec-
tive associations of bisphenol A with low-grade albuminuria
and cardiovascular risk in future when the data are available.
Second, urinary albumin excretion was assessed in a single
urine sample. We acknowledge that a 24-h urine sample or
three samples from 3 consecutive days would provide more
stable measures for urinary albumin excretion.26 However, it
was reported that the use of spot specimens for urinary
albumin-to-creatinine ratio was more convenient for a large
cohort sample and well agreed with 24-h urinary albumin
excretion, and could be used as a reliable alternative to 24-h
urinary albumin excretion or multiple samples in large
epidemiological research.47,48
In conclusion, this study demonstrated that bisphenol A
exposure was associated with an increased risk of low-grade
albuminuria in Chinese adults. Further follow-up studies are
warranted to validate our findings.
MATERIALS AND METHODS
Study design and participants
A cross-sectional study was conducted to investigate the association
between bisphenol A exposure and the human health outcomes in
Chinese adults. The study population, design, and protocols have
been described previously.49 Briefly, in June–July 2008, we performed
an investigation in a population selected from Songnan Community,
Baoshan District, Shanghai metropolitan area, China. As our major
interest was focused on the effects of bisphenol A exposure on
chronic diseases, we conducted the investigation in residents aged
40 years or older. A total of 10,185 participants were included in the
screening examination. Participants were classified into one of three
groups according to fasting plasma glucose levels: normal glucose
regulation (fasting plasma glucoseo5.6mmol/l and without dia-
betes history), impaired glucose regulation (5.6pfasting plasma
glucoseo7.0mmol/l and without diabetes history), and diabetes
(fasting plasma glucoseX7.0mmol/l or with history of diabetes).
In June–August 2009, participants were randomly selected from
these groups for further investigation, which included a detailed
questionnaire, anthropometric measurement, a 75-g OGTT, and
blood and urine sampling. Our selection was based on a ratio of 1.0
(diabetes):1.2 (impaired glucose regulation):1.44 (normal glucose
regulation) because subjects with lower glucose levels might have a
lower participation rate than those with higher glucose levels.
Among 3455 study participants with blood and urine samples
included in the second survey, 400 participants with macroalbu-
minuria (urinary albumin-to-creatinine ratioX300mg/g, n¼ 67) or
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microalbuminuria (30mg/gpurinary albumin-to-creatinine ratio
o300mg/g, n¼ 333) were excluded from the analysis for risk
of low-grade albuminuria. Thus, 3055 participants with urinary
albumin-to-creatinine ratio less than the current microalbuminuria
threshold (30mg/g) were included in the current analysis for the
association of low-grade albuminuria with bisphenol A exposure.
The participants (3055 subjects) and the nonparticipants (7130
subjects) were similar in characteristics such as sex and age.
All study participants provided written informed consent, and
the Committee on Human Research at the Jiao-Tong University
School of Medicine Rui-Jin Hospital approved the study protocol.
Clinical evaluation
The information of sociodemographics, medical history, family
history, and lifestyle factors was collected through face-to-face
interviews by trained personnel. All participants underwent a
physical examination including measurement of weight, height,
waist circumference, systolic blood pressure, and diastolic blood
pressure. Blood pressure was measured at nondominant arm in a
seated position after a 5-min rest, using an automated electronic
device (OMRON Model HEM-752 FUZZY, Omron, Dalian, China).
Three measurements were taken 1min apart, and an average of the
three was used in analysis. Body mass index was calculated by
dividing weight (in kg) by the square of height (in meters).
Subjects were admitted after an overnight fast of 410 h and
underwent a 75-g OGTT. The fasting and OGTT 2-h venous blood
samples were collected into a routine tube, respectively, and were
immediately processed by centrifugation at 4 1C for 5min at 4000
relative centrifugal force. Fasting plasma glucose, post-loading
plasma glucose, fasting and post-loading serum insulin concen-
trations, serum creatinine, lipids profile including triglycerides,
high-density lipoprotein cholesterol, low-density lipoprotein choles-
terol, and high-sensitivity C-reactive protein were detected within
1 h of collection. Another anticoagulated venous blood (heparin)
was collected for measurement of hemoglobin A1c within 4 h of
collection.
Venous plasma glucose level was measured by glucose
oxidase method (ADVIA-1650 Chemistry System, Bayer, Leverku-
sen, Germany), hemoglobin A1c was measured by high-performance
liquid chromatography (BIO-RAD, Hercules, CA), and serum
insulin concentrations were measured by an electrochemilumines-
cence assay (Roche-Diagnostics, Basel, Switzerland). Serum creati-
nine, triglycerides, total cholesterol, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, and high-sensitivity
C-reactive protein were measured with an autoanalyzer (ADVIA-
1650 Chemistry System, Bayer). HOMA-IR was calculated as fasting
insulin (mIU/ml) fasting plasma glucose (mmol/l)/22.5.
Estimated glomerular filtration rate expressed in ml/min per
1.73m2 was calculated by the abbreviated modification of diet in
renal disease formula recalibrated for Chinese:50 estimated glomerular
filtration rate¼ 186 (serum creatinine value 0.011)1.154
(age)0.203 (0.742 if female) 1.233, where serum creatinine value
is serum creatinine expressed as mmol/l and 1.233 is the adjusting
coefficient for Chinese.
Urinary albumin excretion
The single-void first morning urine samples were collected into two
bisphenol A–free urine containers. One was assessed for the urinary
albumin-to-creatinine ratio within 1 h after sample collection.
Another was stored at 70 1C within 4 h after sample collection
until other measurements were recorded.
Urinary albumin concentration was determined by immunotur-
bidimetry (Beijia Biochemistry, Shanghai, China), and urinary
creatinine concentration was measured by a modified Jaffe method
on an automatic analyzer (Beckman LX/20, Brea, CA). Urinary
albumin-to-creatinine ratio was calculated by dividing the urinary
albumin concentrations by the urinary creatinine concentrations
and expressed in mg/g.
The definition of low-grade albuminuria was according to the
highest quartile of urinary albumin-to-creatinine ratio in partici-
pants without micro- and macroalbuminuria. Quartile ranges
for urinary albumin-to-creatinine ratio were as follows: 0–2.50,
2.51–5.03, 5.04–9.70, and 9.71–29.9mg/g.
Quantification of urinary bisphenol A concentration
The urine samples stored at 70 1C within 4 h after sample collec-
tion were thawed and measured for total (free and conjugated)
urinary bisphenol A concentration at the Shanghai Institute of
Materia Medica, Chinese Academy of Sciences, and determined
after enzymatic hydrolysis by a sensitive and selective liquid
chromatography–tandem mass spectrometry method as previously
described.49
The intra- and inter-day relative s.d., calculated from quality
control samples (0.80, 10.0, and 80.0 ng/ml), were both below 8.7%.
The inter-day relative error as determined from quality control
samples was within 2.5%. The lower limit of detection for bisphenol
A concentrations, at which both precision and accuracy were
o9.1%, was 0.30 ng/ml. The results of stability experiments showed
that no significant degradation occurred during sample incubation,
chromatography, and extraction processes for bisphenol A in urine
samples (deviating no 47.4% at low and high nominal concentra-
tions). The analytical data demonstrated excellent reproducibility,
specificity, sensitivity, and precision for measurement of urinary
bisphenol A concentrations.
Statistical analysis
There were large variations in bisphenol A concentrations in the
urinary samples, and the data were not normally distributed. The
bisphenol A concentrations were logarithmically transformed, and
median with interquartile range and quartiles were used to describe
the results. Bisphenol A results less than the lower limit of detection
(n¼ 369/3055) were replaced with a value equal to the lower limit of
detection divided by 2 in order to distinguish a non-detectable
laboratory test result from a measured laboratory test result.51
Statistical analysis was performed with SAS 8.1 (SAS Institute,
Cary, NC). Continuous variables were summarized by means and
s.d. for normally distributed data or medians and interquartile
ranges for non-normally distributed data. Urinary albumin-to-
creatinine ratio, triglycerides, fasting plasma glucose, post-loading
plasma glucose, hemoglobin A1c, HOMA-IR, and high-sensitivity
C-reactive protein levels were logarithmically transformed to achieve
a normal distribution. All categorical parameters were summarized
as numbers and proportions.
Pearson’s correlation coefficients of urinary albumin-to-
creatinine ratio with potential confounding factors were calculated.
The variables that were significant at Po0.20 level in Pearson’s
correlations were put into the multiple stepwise linear regression
models to identify the independent determinants of urinary
albumin-to-creatinine ratio.
Univariable logistic regression models were first fitted to
evaluate the crude association between bisphenol exposure and
low-grade albuminuria. In the multivariable logistic regression
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models, we adjusted for the potential confounding factors including
age, sex, smoking and drinking status, the use of angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker drugs,
body mass index, systolic blood pressure, diastolic blood pressure,
high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol, estimated glomerular filtration rate, fasting plasma
glucose, post-loading plasma glucose, hemoglobin A1c, HOMA-IR,
and high-sensitivity C-reactive protein. Urinary bisphenol A con-
centration was analyzed as both a continuous (in the unit of s.d. of
log-bisphenol A) and a categorical variable (in quartiles) in separate
analyses.
We further performed stratified analyses on the associations
between bisphenol A exposure and the risk of low-grade
albuminuria by the major risk factors including age, sex, smoking
and drinking status, body mass index, hypertension, diabetes
according to OGTT diagnosis criteria, hemoglobin A1c, estimated
glomerular filtration rate, and high-sensitivity C-reactive protein.
The interaction tests were conducted by introducing the cross-
product terms of the stratum variables and bisphenol A in logistic
regression models.
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